Okko-Sakari Kääriäinen

Okko-Sakari Kääriäinen

Auto-generated profile, based on publicly available information

Okko-Sakari Kääriäinen

Department of Oncology, Kuopio University Hospital, Kuopio, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
TKTimo Kiljunen
Timo Kiljunen
SASaad Akram
Saad Akram
JNJarkko Niemelä
Jarkko Niemelä
ELEliisa Löyttyniemi
Eliisa Löyttyniemi
JSJan Seppälä
Jan Seppälä
JKJani Keyriläinen
Jani Keyriläinen
A commercial deep learning (DL)-based automated segmentation tool (AST) for computed tomography (CT) is evaluated for accuracy and efficiency gain within prostate cancer patients. Thirty patients from six clinics were reviewed with manual- (MC), automated- (AC) and automated and edited (AEC) contouring methods. In the AEC group, created contours (prostate, seminal vesicles, bladder, rectum, femoral heads and penile bulb) were edited, whereas the MC group included empty datasets for MC. In one clinic, lymph node CTV delineations were evaluated for interobserver variability. Compared to MC, the mean time saved using the AST was 12 min for the whole data set (46%) and 12 min for the lymph node CTV (60%), respectively. The delineation consistency between MC and AEC groups according to the Dice similarity coefficient (DSC) improved from 0.78 to 0.94 for the whole data set and from 0.76 to 0.91 for the lymph nodes. The mean DSCs between MC and AC for all six clinics were 0.82 for prostate, 0.72 for seminal vesicles, 0.93 for bladder, 0.84 for rectum, 0.69 for femoral heads and 0.51 for penile bulb. This study proves that using a general DL-based AST for CT images saves time and improves consistency.

26 September 2022 in Cancer Medicine
Verified
Journal Article
Open access
AHAnniina Hyväkkä
Anniina Hyväkkä
OKOkko‐Sakari Kääriäinen
Okko‐Sakari Kääriäinen
TUTapio Utriainen
Tapio Utriainen
ELEliisa Löyttyniemi
Eliisa Löyttyniemi
MKMattila Ensio Kalle
Mattila Ensio Kalle
MSMaria Sundvall
Maria Sundvall
Background: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRPC) with bone metastases. However, real‐world data are also needed with wider inclusion criteria.Methods: We report results of a retrospective multicenter study including all patients with metastatic CRPC treated with radium‐223 in all five university hospitals in Finland since the introduction of the treatment. We identified 160 patients who had received radium‐223 in Finland in 2014–2019.Results: The median overall survival (OS) was 13.8 months (range 0.5–57 months), and the median real‐world progression‐free survival (rwPFS) was 4.9 months (range 0.5–29.8 months). Alkaline phosphatase (ALP) values within the normal range before and during the radium‐223 treatment or the reduction of elevated ALP to normal range during treatment were associated with better OS when compared to elevated ALP values before and during treatment (p < 0.0001). High prostate‐specific antigen (PSA) level (≥100 μg/L) before radium‐223 treatment was associated with poor OS compared to low PSA level (<20 μg/L) (p = 0.0001). Most patients (57%) experienced pain relief. Pain relief indicated better OS (p = 0.002). Radium‐223 treatment was well tolerated. Toxicity was mostly low grade. Only 12.5% of the patients had grade III–IV adverse events, most commonly anemia, neutropenia, leucopenia, and thrombocytopenia.Conclusion: Radium‐223 was well tolerated in routine clinical practice, and most patients achieved pain relief. Pain relief, ALP normalization, lower baseline PSA, and PSA decrease during radium‐223 treatment were prognostic for better survival. The efficacy of radium‐223 in mCRPC as estimated using OS was comparable to earlier randomized trial in this retrospective real‐world study. Our results support using radium‐223 for mCRPC patients with symptomatic bone metastases even in the era of new‐generation androgen receptor‐targeted agents.

23 May 2024 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
KJKatriina J. Jalkanen
Katriina J. Jalkanen
EAErika Alanne
Erika Alanne
SISanna Iivanainen
Sanna Iivanainen
OKOkko-Sakari Kääriäinen
Okko-Sakari Kääriäinen
MTMinna Tanner
Minna Tanner
MMMika Mustonen
Mika Mustonen

11 November 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
OKOkko-Sakari Kääriäinen
Okko-Sakari Kääriäinen
PPPekka Poutiainen
Pekka Poutiainen
HGHeidi Gröhn
Heidi Gröhn
TVTimo Voivalin
Timo Voivalin
HMHanna Mussalo
Hanna Mussalo
PAPäivi Auvinen
Päivi Auvinen
Background and purpose: Radioligand therapy targeting prostate-specific membrane antigen (PSMA) with lutetium-177 PSMA (¹⁷⁷Lu-PSMA) compounds has emerged as an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The KuPSMALu trial evaluated the real-world efficacy and safety of in-house produced ¹⁷⁷Lu-PSMA imaging & therapy (I&T) for mCRPC patients in a public healthcare setting and assessed whether selection based on ¹⁸F-PSMA-PET and contrast-enhanced CT – without FDG-PET – provides favourable oncological outcomes. Patients/material and methods: This prospective, single-centre observational study included 40 patients with PSMA-positive mCRPC who had progressed after chemotherapy and at least one androgen receptor pathway inhibitor. Patients received 3–6 cycles of ¹⁷⁷Lu-PSMA-I&T at 6–8-week intervals. Imaging, blood-based markers and patient-reported outcomes were collected longitudinally. Dosimetry, adverse events (AEs) and quality-of-life metrics were systematically assessed. Results: The median overall survival (mOS) was 16.0 months. ECOG 0–1 patients had significantly longer mOS than ECOG 2 patients (20.0 vs. 4.7 months, p < 0.01). A PSA decrease ≥ 50% was observed in 40% of patients and correlated with improved mOS (23.7 vs. 9.1 months, p < 0.01). PSA doubling time (dt) > 4 months predicted superior survival (23.8 vs. 12.6 months, p = 0.040). Grade ≥ 3 AEs occurred in only 12.3% of patients. Interpretation: In-house ¹⁷⁷Lu-PSMA-I&T production combined with pragmatic imaging-based patient selection provides a safe, cost-effective therapy for mCRPC in public healthcare. PSA kinetics, particularly PSA dt, are strong predictors of therapeutic benefit. The findings align with VISION and TheraP trials and highlight the feasibility of integrating radioligand therapy into routine clinical care.

1 September 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
TMTeemu J. Murtola
Teemu J. Murtola
THTuukka Hakkarainen
Tuukka Hakkarainen
MLMari Lahelma
Mari Lahelma
PPPaula Pennanen
Paula Pennanen
RLRiikka-Leena Leskelä
Riikka-Leena Leskelä
ARAntti Rannikko
Antti Rannikko
Prostate cancer is the most prevalent cancer among men in Finland, causing significant healthcare costs. Understanding the economic burden of various treatment pathways is vital for optimizing healthcare strategies. This study aimed at estimating healthcare resource utilization and associated costs for patients with localized prostate cancer (LPC) and locally advanced prostate cancer (LAPC) based on initial treatment decisions in Finland. A retrospective, noninterventional study was conducted using pseudonymized patient-level data from the 5 University Hospitals and the Social Insurance Institution of Finland. The cohort included 16,212 adults diagnosed with localized prostate cancer (LPC) or locally advanced prostate cancer (LAPC) between 1 July 2010 and 30 June 2021. Patients were categorized into 4 groups: no immediate treatment (NIT), radiotherapy only (RT), radiotherapy combined with androgen deprivation therapy (RT+ADT), and radical prostatectomy (RP). Healthcare resource utilization and costs were analyzed on a per-patient-year basis, considering inpatient admissions, outpatient visits, emergency department visits, and outpatient medication costs. The first-year costs were highest for RP (€11,766) and RT+ADT (€10,421), reflecting intensive treatment, followed by RT only (€9,014) and no immediate treatment (NIT) (€4,129). Over time, costs decreased for RP and RT+ADT groups. Emergence of metastatic disease significantly increased costs, particularly due to outpatient medication. Costs began rising 1-2 years before metastasis, indicating early health deterioration. This study highlights significant cost variations across different treatment pathways for prostate cancer in Finland and underscores the economic impact of metastatic disease. Early detection and effective management are essential for cost containment.